On September 30, 2026, CalciMedica, Inc. filed a prospectus supplement with the SEC to offer and sell up to $25,000,000 of its common stock under an at-the-market offering agreement with H.C. Wainwright & Co., dated August 11, 2023. This offering is conducted pursuant to the company's shelf registration statement on Form S-3 (Registration No. 333-293972), which was declared effective on March 11, 2026. The filing includes a legal opinion from Cooley LLP regarding the legality of the shares issuable under the agreement. CalciMedica operates in the biotechnology industry and develops therapies for inflammatory diseases.
